Pfizer Inc. (PFE): what the price assumes

In the published model solve dated 2026-Q2, anchored at $27.96, Pfizer Inc. (PFE) is priced for -2.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-08-07.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/PFE

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.7% sits below it).

How unusual the bet is: n/a

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.8%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Pfizer tells shareholders directly that revenue lost to expiring patents will keep falling through 2030 and that the pace of the decline will accelerate, and that single sentence organizes everything else about the company.
• Against that, the products it has launched or acquired recently grew 18 percent operationally in the quarter ended June 28, 2026, and management lifted the midpoint of full-year revenue guidance to 61.5 billion dollars.
• Watch the write-downs rather than the headline: 4.3 billion dollars of non-cash intangible impairments landed in the June 2026 quarter alone, after 4.9 billion during 2025 and 3.3 billion during 2024.

Bull Case

Start with the thing that scares people, because Pfizer states it more bluntly than any critic would. Its annual report says the company "anticipate[s] a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate". That is the bear case, published by the defendant, and no bull argument that ignores it is worth reading.

Now look at what has actually been arriving while that clock runs. Revenue in the quarter ended June 28, 2026 was 15.0 billion dollars, up 3 percent, and stripping out the two COVID products it rose 5 percent on a currency-neutral basis. The subset management calls launched and acquired products grew 18 percent on that same basis. A company being hollowed out by expiries does not usually produce that number in the middle of the hollowing.

The growth is concentrated and nameable rather than diffuse. In the June quarter Eliquis rose 19 percent operationally, Padcev 23 percent, and the Vyndaqel family 8 percent. In July 2026 the FDA approved Padcev with pembrolizumab as treatment before and after surgery for muscle-invasive bladder cancer regardless of cisplatin eligibility, the first platinum-free regimen cleared for that population. Oncology is where Pfizer spent its acquisition money, and it is where the label expansions are landing.

The cost side has been delivering on a schedule, which is rarer than it sounds. The 10-K reports that "total net cost savings are composed of net cost savings of $5.1 billion achieved through 2025, and the remaining anticipated savings of $600 million, primarily in SI&A, expected to be achieved by the end of 2026". In August the company added an expected 2.5 billion of further productivity savings to be realized from 2027 through 2029. Selling and administrative spending fell 936 million during 2025, of which 930 million came out of marketing. That is a business shrinking its own overhead ahead of a revenue step-down rather than after it.

Then there is the option nobody is being charged much for. In June 2026 Pfizer presented Phase 2b data on berobenatide, an investigational monthly GLP-1 peptide, across three studies in people with obesity or overweight, and said the results support advancing ten Phase 3 studies during 2026 inside a program of more than twenty obesity trials. Monthly dosing, if it holds up, is a different product from weekly dosing in the same class. Research spending backs the ambition: 10.4 billion dollars during 2025.

Here is the structural point a bull can lean on. Today's price does not require Pfizer to grow. It embeds a modest annual contraction in profits over the next several years. Set against 5.1 billion of savings already banked, 2.5 billion more scheduled, and a launched-and-acquired portfolio compounding at eighteen percent, the bar the price sets is not that the patent cliff be avoided. It is that the cliff be no worse than the market already assumes. Meanwhile holders were paid 0.86 dollars a share across the first six months of 2026.

Bear Case

The clearest evidence that Pfizer's competitive position is eroding is not in the revenue line. It is in the write-downs. The company recorded 3.3 billion dollars of intangible asset impairments during 2024, 4.9 billion during 2025, and a further 4.3 billion in the single quarter ended June 28, 2026. Those are product rights Pfizer bought, capitalized, and has now told its auditors are worth less than it paid. Twelve billion dollars of that admission in roughly two and a half years is not an accounting quirk. It is the moat being remeasured.

The consequence shows up where shareholders read it. Pfizer reported a net loss of 248 million dollars for the June 2026 quarter against net income of 2.9 billion in the same quarter a year earlier, and reported diluted results of negative 0.04 per share. For the first six months, reported net income fell to 2.44 billion from 5.88 billion. Adjusted figures excluded the impairments and looked flat. Whether a serial write-down of acquired assets is properly excluded from earnings is a question the reader should hold onto.

Revenue is already contracting before the worst of the expiries arrive. Full-year revenue was 62.6 billion dollars during 2025 against 63.6 billion during 2024. Inside the raised 2026 guidance is a downgrade: management now expects roughly 4 billion from the COVID products rather than roughly 5 billion, with non-COVID products making up the difference. Growth is not being added on top of the base. It is refilling a hole.

The balance sheet limits the response. At March 29, 2026 Pfizer carried 60.6 billion dollars of long-term borrowings plus 3.9 billion falling due within the year, against 1.7 billion of liquid holdings and 11.4 billion in short-term investments. Interest expense ran 2.7 billion during 2025. Management has been explicit about the ranking: no repurchases have been completed during 2026, 3.3 billion of authorization sits unused, and buybacks are described as something to resume "after de-levering our balance sheet". Meanwhile 4.9 billion left as dividends in six months. When a company pays out more than it earns on a reported basis, retires no stock, and still needs to reduce borrowings, the pipeline has to work.

The competitive mechanism itself is unforgiving and Pfizer describes it plainly: generic and biosimilar manufacturers "generally produce identical or highly similar products and sell them for a lower price", and when that competition begins "the resulting price competition can substantially" reduce revenue. There is no execution answer to a molecule going off patent. There is only the next molecule, which is why the obesity and oncology programs carry the weight they do, and why a Phase 2b result is being asked to stand in for a franchise.

Set that against what the price assumes and the bear case sharpens rather than dissolves. Today's price already embeds a contraction in profits of about 4.3 percent a year over the next several years, so the market is not asking for growth. The bear's claim is narrower: that the contraction runs steeper than that once the acceleration the 10-K promises actually begins, and that the write-down cadence is the early reading on it. If so, the methods anchored on book value and on current earnings power become the relevant ones, and the price currently stands roughly 88 percent above where the asset-value family of methods lands and further still above the earnings-power family. There is a long way down to those.

Valuation

The unusual thing about Pfizer's price is what it does not ask for. It embeds no growth at all. Working backward from today's quote, the market is paying for company-wide profits to contract at about 4.3 percent a year over the next several years. Most equity prices carry an expansion assumption; this one carries a managed decline. That changes the question a buyer is answering, from whether the company can grow to whether it can decline more slowly than the market already expects.

Guidance is the first place to test it. Management raised the midpoint of 2026 revenue guidance to 61.5 billion dollars, within a range of 60.5 to 62.5 billion. Revenue was 62.6 billion during 2025 and 63.6 billion during 2024. So even the raised guidance describes a third consecutive year of flat-to-lower revenue, which is roughly the shape the price assumes. The forward question is what happens after 2026, when the annual report says the expiry effect accelerates.

The methods used to triangulate the business split along a line that fits a mature business in decline. The peer-multiple approaches and the forward cash-flow approaches both land close to the current quote, one slightly under it and one slightly over. The approaches built on book value and on current earnings power land far beneath it: the price stands roughly 88 percent above where the asset-value family reaches, and further above the earnings-power family still. When a company is writing down acquired assets at the rate Pfizer is, book-value approaches are marking a moving target, so the gap between those groups is best read as a measure of how much of the value sits in things not yet on the balance sheet.

Basis matters more than usual here. Pfizer's income statement carries no operating profit subtotal; it runs from revenue to income from continuing operations before taxes, a line struck after interest. On that basis the company earned 7.52 billion dollars during 2025 and 7.91 billion over the twelve months through March 29, 2026. Research spending was 10.4 billion during 2025, and intangible impairments of 4.94 billion and restructuring charges of 1.09 billion ran through the same statement. Any single-year profit figure for this company is a statement about how much was written off that year.

Cohort comparison is where the discount becomes visible rather than argued. GILD converts roughly 35 cents of every revenue dollar into operating profit and AMGN roughly 28 cents, both far above what Pfizer manages on a business twice their size. Pfizer trades on a lower multiple of profits than most of that group, which is a fair description of a company whose disclosed products are scheduled to lose exclusivity.

Solvency bounds the downside and constrains the response at the same time. Long-term borrowings stood at 60.6 billion dollars at March 29, 2026 with a further 3.9 billion current, against 1.7 billion of liquid holdings plus 11.4 billion in short-term investments, and interest expense of 2.7 billion ran during 2025. Dividends absorbed 4.9 billion in the first half of 2026, or 0.86 dollars a share, and no stock was repurchased. The dividend is what a holder is paid while the pipeline either replaces the expiring franchises or does not. That, rather than any multiple, is the actual instrument being bought at 25.79 dollars a share.

Catalysts

Pfizer reported second-quarter results on August 4, 2026: revenue of 15.0 billion dollars, up 3 percent and up 1 percent excluding currency, a reported net loss of 248 million driven by 4.3 billion of non-cash intangible impairments, and adjusted diluted earnings of 0.77 per share against 0.78 a year earlier. Management raised the midpoint of full-year revenue guidance by 500 million to a range of 60.5 to 62.5 billion, reaffirmed adjusted diluted earnings guidance of 2.80 to 3.00 per share, and announced an additional 2.5 billion of expected productivity savings to be realized from 2027 through 2029.

The pipeline calendar is where the next real information arrives, and it is unusually dense. In June 2026 the company presented Phase 2b results for berobenatide, an investigational monthly GLP-1 peptide, from the VESPER-1, 2 and 3 studies, and said it plans to start ten Phase 3 studies during 2026 as part of a program of more than twenty obesity trials. In July 2026 the FDA approved Padcev with pembrolizumab before and after surgery for muscle-invasive bladder cancer regardless of cisplatin eligibility. In May 2026 the company reported Phase 2 data for a 25-valent pneumococcal conjugate vaccine candidate in infants. Management flagged several key pivotal readouts over the coming twelve months.

Two corporate items are already scheduled to land in the third quarter. Pfizer completed its licensing transaction with Innovent Biologics on July 10, 2026, bringing a 650 million charge for acquired in-process research and an expected 0.10 per share impact that the reaffirmed full-year guidance already absorbs. Separately, the company announced a chief financial officer transition on June 18, 2026 and reaffirmed full-year guidance the same week, with Cecile Guegan named incoming interim chief financial officer.

Peer Cohorts (Per Segment, With Filing Citations)

Biopharma (reported)

• JNJ (Johnson & Johnson)
• FY2025 10-K: …by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to competitive pressures and the impact of Medicare Part D redesign. Immunology products sales were $15.7 billion in 2025, a decline of 11.8% as compared to the prior year primarily due to the decline of STELARA (ustekinumab)…
• FY2025 10-K: …to innovate and develop new and differentiated products and services that address the evolving healthcare needs of patients, providers and consumers. Development of successful products and technologies is also necessary to offset revenue losses when the Company's existing products lose market share due to various…
• BMY (Bristol-Myers Squibb Company)
• FY2025 10-K: …with symptomatic oHCM to improve functional capacity and symptoms. • U.S. revenues increased 59% in 2025, primarily due to higher demand. • International revenues increased more than 200% in 2025, primarily due to higher demand driven by launches in new markets. Zeposia (ozanimod) - an oral im munomodulatory drug…
• FY2025 10-K: …for the co-development and co-commercialization of pumitamig (BNT327/BMS986545), a bispecific antibody targeting PD-L1 and VEGF-A, which is currently being evaluated in several indications, including in CRC, ES-SCLC, NSCLC and TNBC. The companies will jointly develop and commercialize pumitamig as monotherapy and in…
• AMGN (Amgen Inc.)
• FY2025 10-K: …develop and commercialize innovative products and acquire or collaborate on therapies currently in development by other companies. We must grow sales from existing and new products to achieve revenue growth and to offset revenue losses caused by products' loss of their exclusivity or launches of competing products.…
• FY2025 10-K: CIA provides for such a pathway. Discussions within the FDA and other regulatory authorities, and between regulatory authorities and sponsors, continue as to the evidence needed to demonstrate biosimilarity or interchangeability for specific products. See We currently face competition from biosimilars and generics and…
• GILD (GILEAD SCIENCES, INC.)
• FY2025 10-K: …activity to drive innovation and growth of our business. We extensively outsource our clinical trial activities and usually perform only a small portion of start-up activities in-house. We rely on third-party contract research organizations to perform most of our clinical studies, including document preparation, site…
• FY2025 10-K: …we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and…
• GSK (GSK plc)
• FY2025 20-F: …the right place . The biopharma sector continues to grow as demand increases. $2.4trn 46% 9.3% The global medicine market - using invoice price levels - is expected to grow at 5-8% CAGR, reaching about $2.4 trillion by 2029. 8 Specialty medicines are projected to represent about 46% of global spending in 2029, up…
• FY2025 20-F: …leadership in international science. In 2025, the share of drug licensing deals involving Chinese assets was anticipated to reach almost 40%, compared to fewer than 5% in 2020 . 1 Even as pricing pressure intensifies, governments continue to look to the biopharma industry as a strategic driver of innovation and…
• NVS (Novartis AG)
• FY2025 20-F: …approval in China in the second and fourth quarter of 2025, respectively, as the first and only selective endothelin A (ETA) receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN). Immunology Net sales in the immunology therapeutic area reached USD 10.3 billion (+11%, +10% cc), with sales…
• FY2025 20-F: S. The FDA continues to monitor the safety of pharmaceutical products after they have been approved for sale in the US market. The pharmaceutical development and registration process is typically intensive, lengthy and rigorous. When a pharmaceutical company has gathered data that it believes sufficiently demonstrates…
• LLY (ELI LILLY & Co)
• FY2025 10-K: …with other pharmaceutical companies. For additional information, see Item 8, "Financial Statements and Supplementary Data-Note 3: Collaborations and Other Arrangements." Competition Our products compete globally with many other pharmaceutical products in highly competitive markets. Important competitive factors…
• FY2025 10-K: …China and other markets where research and development capabilities have expanded and accelerated significantly. In many cases, our products compete against the leading products of one or more of our competitors. To compete successfully in a highly competitive and increasingly fast-paced global environment, we must…
• ABBV (AbbVie Inc.)
• FY2025 10-K: …companies that research, develop, manufacture, market and sell proprietary pharmaceutical products and biologics. All of these competitors may introduce new products or develop technological advances that compete with AbbVie's products in therapeutic areas such as immunology, neuroscience, oncology and aesthetics. In…
• FY2025 10-K: …a biosimilar product that is determined to be "interchangeable" will be considered by the FDA as substitutable for the original biologic product without the intervention of the health care provider who prescribed the original biologic product. To prove that a biosimilar product is interchangeable, the applicant must…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.